Evercore Wealth Management LLC increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.0% during the second quarter, according to its most recent filing with the SEC. The fund owned 281,316 shares of the company’s stock after buying an additional 15,849 shares during the period. Thermo Fisher Scientific accounts for 1.8% of Evercore Wealth Management LLC’s portfolio, making the stock its 12th largest position. Evercore Wealth Management LLC owned about 0.07% of Thermo Fisher Scientific worth $41,568,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. Mycio Wealth Partners LLC boosted its stake in shares of Thermo Fisher Scientific by 1.6% in the second quarter. Mycio Wealth Partners LLC now owns 711 shares of the company’s stock valued at $105,000 after buying an additional 11 shares during the period. Signaturefd LLC boosted its stake in shares of Thermo Fisher Scientific by 10.6% in the second quarter. Signaturefd LLC now owns 842 shares of the company’s stock valued at $124,000 after buying an additional 81 shares during the period. Cedar Wealth Management LLC boosted its stake in shares of Thermo Fisher Scientific by 33.0% in the second quarter. Cedar Wealth Management LLC now owns 1,377 shares of the company’s stock valued at $203,000 after buying an additional 342 shares during the period. Bridgeway Capital Management Inc. bought a new stake in shares of Thermo Fisher Scientific during the second quarter valued at about $207,000. Finally, Counsel Portfolio Services Inc. bought a new stake in shares of Thermo Fisher Scientific during the second quarter valued at about $236,000. 87.80% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Thermo Fisher Scientific Inc. (NYSE:TMO) opened at 151.25 on Friday. The firm’s 50 day moving average price is $152.92 and its 200-day moving average price is $151.85. The stock has a market cap of $59.75 billion, a price-to-earnings ratio of 30.23 and a beta of 1.24. Thermo Fisher Scientific Inc. has a 1-year low of $119.75 and a 1-year high of $160.68.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, October 27th. The company reported $2.03 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.97 by $0.06. The business earned $4.49 billion during the quarter, compared to the consensus estimate of $4.39 billion. Thermo Fisher Scientific had a net margin of 11.10% and a return on equity of 14.95%. The company’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.80 earnings per share. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post $8.25 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, January 16th. Shareholders of record on Thursday, December 15th will be paid a $0.15 dividend. The ex-dividend date of this dividend is Tuesday, December 13th. This represents a $0.60 annualized dividend and a dividend yield of 0.40%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 12.00%.

Several brokerages have issued reports on TMO. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $178.00 target price on the stock in a research report on Monday, August 1st. Citigroup Inc. increased their price objective on Thermo Fisher Scientific from $160.00 to $182.00 and gave the company a “buy” rating in a report on Friday, July 29th. JPMorgan Chase & Co. started coverage on Thermo Fisher Scientific in a report on Thursday, September 22nd. They set an “overweight” rating and a $180.00 price objective for the company. Jefferies Group reiterated a “hold” rating on shares of Thermo Fisher Scientific in a report on Thursday, August 4th. Finally, Leerink Swann started coverage on Thermo Fisher Scientific in a report on Thursday. They set an “outperform” rating and a $175.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $164.37.

In other Thermo Fisher Scientific news, insider Thomas W. Loewald sold 913 shares of the business’s stock in a transaction on Friday, August 26th. The shares were sold at an average price of $151.92, for a total value of $138,702.96. Following the completion of the transaction, the insider now owns 39,983 shares in the company, valued at $6,074,217.36. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 28,797 shares of the business’s stock in a transaction on Friday, September 2nd. The stock was sold at an average price of $151.01, for a total transaction of $4,348,634.97. Following the completion of the transaction, the chief executive officer now owns 307,444 shares of the company’s stock, valued at approximately $46,427,118.44. The disclosure for this sale can be found here. 0.52% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company is a provider of analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

5 Day Chart for NYSE:TMO

Receive News & Stock Ratings for Thermo Fisher Scientific Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc. and related stocks with our FREE daily email newsletter.